CDK4 and sarcoma: Despite the fact that a valuable predictive biomarker selection for CDK4/6 inhibition is challenging, the selected biomarkers with RNA overexpression of CDK4 and no overexpression of CDKN2A seem adequate for future studies with CDK4/6 inhibitors in sarcomas.